A Simple Key For Glibornuride Unveiled
All enrolled clients who been given no less than 1 dose of zosuquidar or placebo during induction had been monitored with the incidence of adverse situations (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse gatherings were relevant to the duration of extended and major myelosuppression as is expected with induction chem